Alkermes ALKS Equity Research 2016

Equity research report on Alkermes covering approved drugs including Vivitrol and Aristada for CNS indications, along with pipeline candidates in depression, schizophrenia, multiple sclerosis, and immuno-oncology. Report highlights Alkermes as a potential power house in the CNS market.